Predicting Cancer Risk With Digital and Molecular Markers

Launched by UNIVERSITY OF ERLANGEN-NÜRNBERG MEDICAL SCHOOL · Apr 29, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on finding new ways to predict the risk of developing certain types of cancer, particularly breast cancer. Researchers will look at information from both cancer patients and healthy individuals to identify differences that may indicate a higher risk for developing cancer. These differences could include specific biological markers, lifestyle choices, or family health history.

To participate in this study, women aged 18 and older who have a smartphone capable of running a specific app called BayPass are eligible. Participants must also be willing to consent to the study and share their personal data. Those currently diagnosed with breast, lung, colorectal, or gynecologic cancers can join as part of the case group. During the trial, participants can expect to contribute information that may help researchers better understand cancer risks, ultimately aiming to improve early detection and prevention strategies. It's important to note that individuals with certain health conditions, such as HIV or severe illnesses, are not eligible to participate.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Biological adult (at least 18 years old) women
• • 2. Written informed consent for study participation and processing of personal data
• • 3. Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes
• Additional inclusion criterion for case group:
• • 4. Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)
• Exclusion Criteria:
• • 1. Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection
• • 2. Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4